To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 125 participants.
Also called NCT06646354
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT06646354
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT06646354. Randomized; double masking; primary purpose treatment. Start 2025-04-22 (actual); primary completion 2025-05-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
- Acronym
- HODO-2224
- Condition
- Hypertension
- Condition
- Primary Hypercholesterolaemia
- Intervention (Drug)
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
- Intervention (Drug)
- Candesartan/Amlodipine
- Intervention (Drug)
- Candesartan/Rosuvastatin/Ezetimibe
- Lead sponsor
- Hyundai Pharm
Record details
- Record id
cardio:ct-nct06646354- Content hash
556446c20c043b981ae893b49ce27df836104f5057b80f9711b996c883f27237